<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02916420</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-135-Ⅲ</org_study_id>
    <nct_id>NCT02916420</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma</brief_title>
  <official_title>A Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the efficacy and safety of pomalidomide in combination with&#xD;
      low-dose dexamethasone in Chinese patients with relapsed and refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pomalidomide plus low-dose Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>4mg/day, d1-d21, 28 days per cycle</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>≤70 years,40mg/day; &gt;70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a documented diagnosis of multiple myeloma&#xD;
&#xD;
          -  Subjects must have received at least 2 prior therapies. Subjects must have undergone&#xD;
             prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of&#xD;
             bortezomib (either in separate regimens or within the same regimen). Subjects must&#xD;
             also have documented evidence of progressive disease(PD) during or within 60 days&#xD;
             (measured from the end of the last cycle) of completing treatment with the last&#xD;
             anti-myeloma drug regimen used just prior to study entry.&#xD;
&#xD;
          -  Subjects must have measurable disease: serum M-protein ≥ 5 g/L or urine M-protein ≥&#xD;
             200 mg/24 hours or the involved free light chain being ≥100 mg/L when serum free light&#xD;
             chain ratio (κ/λ ratio &lt; 0.26 or &gt; 1.65) is abnormal&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score ≤2&#xD;
&#xD;
          -  Life expectancy &gt;3 months&#xD;
&#xD;
          -  For female patients,&#xD;
&#xD;
               -  naturally postmenopausal for at least 24 months, or take surgical sterilization&#xD;
&#xD;
               -  Women of childbearing potential must:&#xD;
&#xD;
                    1. have 2 negative pregnancy tests before initiating pomalidomide. The first&#xD;
                       test should be performed within 10-14 days, and the second test within 24&#xD;
                       hours prior to initiating pomalidomide&#xD;
&#xD;
                    2. commit either to abstain continuously from heterosexual sexual intercourse&#xD;
                       or to use 2 methods of reliable birth control, beginning 4 weeks prior to&#xD;
                       initiating pomalidomide treatment, during therapy, and continuing for 4&#xD;
                       weeks following discontinuation of pomalidomide therapy&#xD;
&#xD;
                    3. agree to perform the pregnancy testing during the study&#xD;
&#xD;
          -  Male patients must always use a condom during any sexual contact with females of&#xD;
             reproductive potential while taking pomalidomide and for up to 4 weeks after&#xD;
             discontinuing pomalidomide, even if they have undergone a successful vasectomy.&#xD;
             Meanwhile male patients taking pomalidomide must not donate sperm.&#xD;
&#xD;
          -  Subjects agree not to share medication with another person&#xD;
&#xD;
          -  Subjects are able to adhere to the study visit schedule and other protocol&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any serious medical conditions, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the patient from complying to the protocol or put the patient's safety&#xD;
             at risk&#xD;
&#xD;
          -  Evidence of uncontrolled cardiovascular disease, such as congestive heart failure,&#xD;
             unstable angina, myocardial infarction within 12 months prior to enrollment&#xD;
&#xD;
          -  Any of the following laboratory abnormalities:&#xD;
&#xD;
               -  ANC &lt; 1×10^9/L&#xD;
&#xD;
               -  PLT &lt; 75×10^9/L for subjects in whom &lt;50% of bone marrow nucleated cells are&#xD;
                  plasma cells; or PLT &lt; 30×10^9/L for subjects in whom ≥50% of bone marrow&#xD;
                  nucleated cells are plasma cells&#xD;
&#xD;
               -  Creatinine Clearance &lt; 45 mL/min&#xD;
&#xD;
               -  AST or ALT &gt; 3.0 x ULN&#xD;
&#xD;
               -  Serum total bilirubin &gt; 34.2 μmol/L&#xD;
&#xD;
               -  Corrected serum calcium &gt; 3.5 mmol/L&#xD;
&#xD;
               -  Hemoglobin &lt; 80g/L&#xD;
&#xD;
          -  Prior history of malignancies, other than multiple myeloma, unless the subject has&#xD;
             been free of the disease for ≥ 3 years. Exceptions include the following:&#xD;
&#xD;
               -  Basal or Squamous cell carcinoma of the skin&#xD;
&#xD;
               -  Carcinoma in situ of the cervix or breast&#xD;
&#xD;
               -  Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)&#xD;
&#xD;
          -  Serious, uncontrolled medical conditions or active infection, including but not&#xD;
             limited to HIV antibody positive, HBsAg positive and HBV DNA copies &gt; 1 × 10^3,&#xD;
             hepatitis C virus antibody positive, uncontrolled diabetes, patients requiring&#xD;
             hemodialysis&#xD;
&#xD;
          -  Hypersensitivity to thalidomide, lenalidomide, or dexamethasone&#xD;
&#xD;
          -  Previous therapy with pomalidomide&#xD;
&#xD;
          -  Peripheral neuropathy ≥ Grade 2&#xD;
&#xD;
          -  Incidence of gastrointestinal disease that may significantly alter the absorption of&#xD;
             pomalidomide&#xD;
&#xD;
          -  Subjects who received any of the following within the last 14 days of initiation of&#xD;
             study treatment: plasmapheresis, major surgery, radiation therapy, or use of any&#xD;
             anti-myeloma drug therapy&#xD;
&#xD;
          -  Use of any investigational drugs within 28 days prior to enrollment&#xD;
&#xD;
          -  Subjects with conditions requiring chronic steroid or immunosuppressive treatment,&#xD;
             such as rheumatoid arthritis, multiple sclerosis, and lupus, etc.&#xD;
&#xD;
          -  Patients unable or unwilling to undergo antithrombotic prophylactic treatment&#xD;
&#xD;
          -  Subjects who received an allogeneic hematopoietic stem cell transplant less than 12&#xD;
             months prior to enrollment&#xD;
&#xD;
          -  Subjects who are planning for or eligible for hematopoietic stem cell transplant&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lugui Qiu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood Diseases Hospital Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lugui Qiu, MD</last_name>
    <phone>86-022-27218738</phone>
    <email>qiulg@ihcams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blood Diseases Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>September 24, 2016</study_first_submitted>
  <study_first_submitted_qc>September 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

